Skip to search formSkip to main contentSkip to account menu

Deprenyl

National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Antiparkinson AgentsMonoamine Oxidase InhibitorsPhenethylaminesSelegiline
Selegiline, (R,S)-Isomer

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1999
Highly Cited
1999
Dopamine and glutamate neurotoxicity in cultured chick telencephali cells: effects of nmda antagonists, antioxidants and mao inhibitors
Review
1997
Review
1997
Parkinson's disease: prospects for improved drug therapy.
1988
1988
Amino Acid Availability and Brain Function in Health and Disease
Until the early seventies, it was generally believed that normal brain function would be unaffected by the metabolic changes… 
1986
1986
Demonstration of monoamine oxidase type B in serotonergic and type A in noradrenergic neurons in the cat dorsal pontine tegmentum by an improved histochemical technique
1986
1986
Depletion of striatal β-phenylethylamine following dopamine but not 5-HT denervation
Highly Cited
1985
Highly Cited
1985
Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse.
Highly Cited
1981
Highly Cited
1981
Deprenyl in Parkinson disease
(–)Deprenyl, a specific monoamine oxidase subtype B inhibitor (MAOI-B), has been reported to be a safe and valuable adjunct to… 
1980
1980
Studies on the subcellular localization of monoamine oxidase types A and B and its importance for the deamination of dopamine in the rat brain.
Highly Cited
1976
Highly Cited
1976
Properties of monoamine oxidase in mouse neuroblastoma N1E-115 cells.
Highly Cited
1975
Highly Cited
1975
Multiple forms of monoamine oxidase in rabbit platelets.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)